Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients
SC Cheatham, MR Fleming, DP Healy… - International journal of …, 2013 - Elsevier
… in various patient populations, published PK data in obesity are limited to a … steady-state
pharmacokinetics of piperacillin and tazobactam administered by prolonged infusion in obese …
pharmacokinetics of piperacillin and tazobactam administered by prolonged infusion in obese …
Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients
EK Chung, SC Cheatham, MR Fleming… - … Pharmacology, 2015 - Wiley Online Library
… /tazobactam in hospitalized obese and nonobese patients. Therefore, the … steady-state
population pharmacokinetics of piperacillin and tazobactam, administered by prolonged infusion, …
population pharmacokinetics of piperacillin and tazobactam, administered by prolonged infusion, …
Population pharmacokinetics and pharmacodynamics of extended-infusion piperacillin and tazobactam in critically ill children
K Nichols, EK Chung, CA Knoderer… - Antimicrobial agents …, 2016 - Am Soc Microbiol
… the steady-state population pharmacokinetics of piperacillin and tazobactam when administered
by extended infusion in … Additionally, we evaluated the pharmacodynamics of TZP using …
by extended infusion in … Additionally, we evaluated the pharmacodynamics of TZP using …
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis
… On Day 2 (fifth piperacillin/tazobactam bolus dose or change … that continuous infusion of
piperacillin maintains superior … in critically ill patients with sepsis at first dose and at steady state. …
piperacillin maintains superior … in critically ill patients with sepsis at first dose and at steady state. …
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients
AW Sturm, N Allen, KD Rafferty, DN Fish… - … Pharmacology and …, 2014 - Wiley Online Library
… patient population, the purpose of this study was to evaluate the steady-state
pharmacokinetic-pharmacodynamic … regimens were apparently negated, and the use of extended …
pharmacokinetic-pharmacodynamic … regimens were apparently negated, and the use of extended …
Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic …
KM Shea, SC Cheatham, DW Smith… - Annals of …, 2009 - journals.sagepub.com
… Steady-state pharmacokinetic data were obtained from 13 patients who received
piperacillin/tazobactam 4.5 g every 8 hours, infused over 4 hours. Monte Carlo simulations (10,000 …
piperacillin/tazobactam 4.5 g every 8 hours, infused over 4 hours. Monte Carlo simulations (10,000 …
[HTML][HTML] Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
JJ Veillette, SA Winans, VK Maskiewicz… - … and Pharmacokinetics, 2021 - Springer
… 6 h in hemodialysis patients to a 27 g/24-h continuous infusion in a patient with a short PT
half-… Predicted free steady-state piperacillin troughs on 4.5 g every 6 h are displayed in Fig. 1, …
half-… Predicted free steady-state piperacillin troughs on 4.5 g every 6 h are displayed in Fig. 1, …
Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual
D Newman, MH Scheetz, OA Adeyemi… - Annals of …, 2007 - journals.sagepub.com
… a reduced average serum steady-state concentration: 39.8 mg/… dosing schemes with
piperacillin/tazobactam. Future studies … or continuous infusion dosing schemes for obese …
piperacillin/tazobactam. Future studies … or continuous infusion dosing schemes for obese …
Dosing of piperacillin/tazobactam in a morbidly obese patient
H Deman, J Verhaegen, L Willems… - Journal of antimicrobial …, 2012 - academic.oup.com
… A free fraction of 70% was used, as piperacillin/tazobactam is known to be approximately
30… patient, were compared with the parameters determined at the same dose at steady state in …
30… patient, were compared with the parameters determined at the same dose at steady state in …
Similar piperacillin/tazobactam target attainment in obese versus nonobese patients despite differences in interstitial tissue fluid pharmacokinetics
D Busse, P Simon, D Petroff, C Dorn, L Schmitt… - Pharmaceutics, 2021 - mdpi.com
… Simulated steady-state concentrations were 1.43-times, 95%CI = (1.27; 1.61), higher in …
We could further show that prolonged and continuous infusions might be necessary for MIC …
We could further show that prolonged and continuous infusions might be necessary for MIC …